STAT5 and Oct-1 Form a Stable Complex That Modulates Cyclin D1 Expression

REFERENCES

• Bertolino, E., and H. Singh. 2002. POU/TBP cooperativity: a mechanism for enhancer action from a distance. Mol. Cell 10: 397–407.
   PubMedGoogle Scholar
• Boulon, S., J. C. Dantonel, V. Binet, A. Vie, J. M. Blanchard, R. A. Hipskind, and A. Philips. 2002. Oct-1 potentiates CREB-driven cyclin D1 promoter activation via a phospho-CREB- and CREB-binding protein-independent mechanism. Mol. Cell. Biol. 22: 7769–7779.
   PubMed Web of Science ®Google Scholar
• Bowman, T., R. Garcia, J. Turkson, and R. Jove. 2000. STATs in oncogenesis. Oncogene 19: 2474–2488.
   PubMed Web of Science ®Google Scholar
• Bradley, H. L., T. S. Hawley, and K. D. Bunting. 2002. Cell intrinsic defects in cytokine responsiveness of STAT5-deficient hematopoietic stem cells. Blood 100: 3983–3989.
   PubMedGoogle Scholar
• Brockman, J. L., M. D. Schroeder, and L. A. Schuler. 2002. PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Mol. Endocrinol. 16: 774–784.
   PubMedGoogle Scholar
• Bromberg, J., and J. E. Darnell. 2000. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468–2473.
   PubMed Web of Science ®Google Scholar
• Cenciarelli, C., F. De Santa, P. L. Puri, E. Mattei, L. Ricci, F. Bucci, A. Felsani, and M. Caruso. 1999. Critical role played by cyclin D3 in the MyoD-mediated arrest of cell cycle during myoblast differentiation. Mol. Cell. Biol. 19: 5203–5217.
   PubMedGoogle Scholar
• Cwirla, S. E., P. Balasubramanian, D. J. Duffin, C. R. Wagstrom, C. M. Gates, S. C. Singer, A. M. Davis, R. L. Tansik, L. C. Mattheakis, C. M. Boytos, P. J. Schatz, D. P. Baccanari, N. C. Wrighton, R. W. Barrett, and W. J. Dower. 1997. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276: 1696–1699.
   PubMed Web of Science ®Google Scholar
• Doubeikovski, A., G. Uzan, Z. Doubeikovski, M. H. Prandini, F. Porteu, S. Gisselbrecht, and I. Dusanter-Fourt. 1997. Thrombopoietin-induced expression of the glycoprotein IIb gene involves the transcription factor PU.1/Spi-1 in UT7-Mpl cells. J. Biol. Chem. 272: 24300–24307.
   PubMedGoogle Scholar
• Dumon, S., S. C. Santos, F. Debierre-Grockiego, V. Gouilleux-Gruart, L. Cocault, C. Boucheron, P. Mollat, S. Gisselbrecht, and F. Gouilleux. 1999. IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line. Oncogene 18: 4191–4199.
   PubMedGoogle Scholar
• Fantl, V., P. A. Edwards, J. H. Steel, B. K. Vonderhaar, and C. Dickson. 1999. Impaired mammary gland development in Cyl-1(−/−) mice during pregnancy and lactation is epithelial cell autonomous. Dev. Biol. 212: 1–11.
   PubMed Web of Science ®Google Scholar
• Feldman, G. M., L. A. Rosenthal, X. Liu, M. P. Hayes, A. Wynshaw-Boris, W. J. Leonard, L. Hennighausen, and D. S. Finbloom. 1997. STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood 90: 1768–1776.
   PubMedGoogle Scholar
• Ford, E., M. Strubin, and N. Hernandez. 1998. The Oct-1 POU domain activates snRNA gene transcription by contacting a region in the SNAPc largest subunit that bears sequence similarities to the Oct-1 coactivator OBF-1. Genes Dev. 12: 3528–3540.
   PubMedGoogle Scholar
• Garcia, J., J. de Gunzburg, A. Eychene, S. Gisselbrecht, and F. Porteu. 2001. Thrombopoietin-mediated sustained activation of extracellular signal-regulated kinase in UT7-Mpl cells requires both Ras-Raf-1- and Rap1-B-Raf-dependent pathways. Mol. Cell. Biol. 21: 2659–2670.
   PubMed Web of Science ®Google Scholar
• Gonzalez, M. I., and D. M. Robins. 2001. Oct-1 preferentially interacts with androgen receptor in a DNA-dependent manner that facilitates recruitment of SRC-1. J. Biol. Chem. 276: 6420–6428.
   PubMedGoogle Scholar
• Gstaiger, M., O. Georgiev, H. van Leeuwen, P. van der Vliet, and W. Schaffner. 1996. The B cell coactivator Bob1 shows DNA sequence-dependent complex formation with Oct-1/Oct-2 factors, leading to differential promoter activation. EMBO J. 15: 2781–2790.
   PubMedGoogle Scholar
• Herber, B., M. Truss, M. Beato, and R. Muller. 1994. Inducible regulatory elements in the human cyclin D1 promoter. Oncogene 9: 1295–1304.
   PubMed Web of Science ®Google Scholar
• Herr, W., and M. A. Cleary. 1995. The POU domain: versatility in transcriptional regulation by a flexible two-in-one DNA-binding domain. Genes Dev. 9: 1679–1693.
   PubMed Web of Science ®Google Scholar
• Hinz, M., D. Krappmann, A. Eichten, A. Heder, C. Scheidereit, and M. Strauss. 1999. NF-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol. 19: 2690–2698.
   PubMed Web of Science ®Google Scholar
• Kang, C. J., C. Sheridan, and M. E. Koshland. 1998. A stage-specific enhancer of immunoglobulin J chain gene is induced by interleukin-2 in a presecretor B cell stage. Immunity 8: 285–295.
   PubMedGoogle Scholar
• Kaushansky, K. 1999. The enigmatic megakaryocyte gradually reveals its secrets. Bioessays 21: 353–360.
   PubMed Web of Science ®Google Scholar
• Kaushansky, K. 1999. Thrombopoietin and hematopoietic stem cell development. Ann. N. Y. Acad. Sci. 872: 314–319.
   PubMedGoogle Scholar
• Kieslinger, M., I. Woldman, R. Moriggl, J. Hofmann, J. C. Marine, J. N. Ihle, H. Beug, and T. Decker. 2000. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev. 14: 232–244.
   PubMed Web of Science ®Google Scholar
• Komatsu, N., H. Nakauchi, A. Miwa, T. Ishihara, M. Eguchi, M. Moroi, M. Okada, Y. Sato, H. Wada, Y. Yawata, et al. 1991. Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colony-stimulating factor, interleukin 3, or erythropoietin for growth and survival. Cancer Res. 51: 341–348.
   PubMed Web of Science ®Google Scholar
• Leonard, W. J., and J. J. O'Shea. 1998. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16: 293–322.
   PubMed Web of Science ®Google Scholar
• Lin, S. Y., W. Xia, J. C. Wang, K. Y. Kwong, B. Spohn, Y. Wen, R. G. Pestell, and M. C. Hung. 2000. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl. Acad. Sci. USA 97: 4262–4266.
   PubMed Web of Science ®Google Scholar
• Lord, J. D., B. C. McIntosh, P. D. Greenberg, and B. H. Nelson. 2000. The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J. Immunol. 164: 2533–2541.
   PubMed Web of Science ®Google Scholar
• Lukas, J., J. Bartkova, M. Rohde, M. Strauss, and J. Bartek. 1995. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol. Cell. Biol. 15: 2600–2611.
   PubMed Web of Science ®Google Scholar
• Martino, A., J. H. T. Holmes, J. D. Lord, J. J. Moon, and B. H. Nelson. 2001. Stat5 and Sp1 regulate transcription of the cyclin D2 gene in response to IL-2. J. Immunol. 166: 1723–1729.
   PubMedGoogle Scholar
• Matsumura, I., J. Ishikawa, K. Nakajima, K. Oritani, Y. Tomiyama, J. Miyagawa, T. Kato, H. Miyazaki, Y. Matsuzawa, and Y. Kanakura. 1997. Thrombopoietin-induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21(WAF1/Cip1) by STAT5. Mol. Cell. Biol. 17: 2933–2943.
   PubMed Web of Science ®Google Scholar
• Matsumura, I., T. Kitamura, H. Wakao, H. Tanaka, K. Hashimoto, C. Albanese, J. Downward, R. G. Pestell, and Y. Kanakura. 1999. Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J. 18: 1367–1377.
   PubMed Web of Science ®Google Scholar
• Matsumura, I., K. Nakajima, H. Wakao, S. Hattori, K. Hashimoto, H. Sugahara, T. Kato, H. Miyazaki, T. Hirano, and Y. Kanakura. 1998. Involvement of prolonged ras activation in thrombopoietin-induced megakaryocytic differentiation of a human factor-dependent hematopoietic cell line. Mol. Cell. Biol. 18: 4282–4290.
   PubMed Web of Science ®Google Scholar
• Misra, V., S. Walter, P. Yang, S. Hayes, and P. O'Hare. 1996. Conformational alteration of Oct-1 upon DNA binding dictates selectivity in differential interactions with related transcriptional coactivators. Mol. Cell. Biol. 16: 4404–4413.
   PubMedGoogle Scholar
• Moriggl, R., V. Gouilleux-Gruart, R. Jahne, S. Berchtold, C. Gartmann, X. Liu, L. Hennighausen, A. Sotiropoulos, B. Groner, and F. Gouilleux. 1996. Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype. Mol. Cell. Biol. 16: 5691–5700.
   PubMed Web of Science ®Google Scholar
• Moriggl, R., D. J. Topham, S. Teglund, V. Sexl, C. McKay, D. Wang, A. Hoffmeyer, J. van Deursen, M. Y. Sangster, K. D. Bunting, G. C. Grosveld, and J. N. Ihle. 1999. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 10: 249–259.
   PubMedGoogle Scholar
• Mui, A. L., H. Wakao, T. Kinoshita, T. Kitamura, and A. Miyajima. 1996. Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. EMBO J. 15: 2425–2433.
   PubMed Web of Science ®Google Scholar
• Onishi, M., T. Nosaka, K. Misawa, A. L. Mui, D. Gorman, M. McMahon, A. Miyajima, and T. Kitamura. 1998. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol. Cell. Biol. 18: 3871–3879.
   PubMed Web of Science ®Google Scholar
• Pallard, C., F. Gouilleux, L. Benit, L. Cocault, M. Souyri, D. Levy, B. Groner, S. Gisselbrecht, and I. Dusanter-Fourt. 1995. Thrombopoietin activates a STAT5-like factor in hematopoietic cells. EMBO J. 14: 2847–2856.
   PubMed Web of Science ®Google Scholar
• Pfitzner, E., R. Jahne, M. Wissler, E. Stoecklin, and B. Groner. 1998. p300/CREB-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transactivation domain of Stat5, but does not participate in the Stat5-mediated suppression of the glucocorticoid response. Mol. Endocrinol. 12: 1582–1593.
   PubMed Web of Science ®Google Scholar
• Porteu, F., M. C. Rouyez, L. Cocault, L. Benit, M. Charon, F. Picard, S. Gisselbrecht, M. Souyri, and I. Dusanter-Fourt. 1996. Functional regions of the mouse thrombopoietin receptor cytoplasmic domain: evidence for a critical region which is involved in differentiation and can be complemented by erythropoietin. Mol. Cell. Biol. 16: 2473–2482.
   PubMed Web of Science ®Google Scholar
• Prefontaine, G. G., M. E. Lemieux, W. Giffin, C. Schild-Poulter, L. Pope, E. LaCasse, P. Walker, and R. J. Hache. 1998. Recruitment of octamer transcription factors to DNA by glucocorticoid receptor. Mol. Cell. Biol. 18: 3416–3430.
   PubMedGoogle Scholar
• Qin, X. F., Y. Luo, H. Suh, J. Wayne, Z. Misulovin, R. G. Roeder, and M. C. Nussenzweig. 1994. Transformation by homeobox genes can be mediated by selective transcriptional repression. EMBO J. 13: 5967–5976.
   PubMedGoogle Scholar
• Rouyez, M. C., C. Boucheron, S. Gisselbrecht, I. Dusanter-Fourt, and F. Porteu. 1997. Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway. Mol. Cell. Biol. 17: 4991–5000.
   PubMed Web of Science ®Google Scholar
• Sabbah, M., D. Courilleau, J. Mester, and G. Redeuilh. 1999. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc. Natl. Acad. Sci. USA 96: 11217–11222.
   PubMed Web of Science ®Google Scholar
• Schindler, U., P. Wu, M. Rothe, M. Brasseur, and S. L. McKnight. 1995. Components of a Stat recognition code: evidence for two layers of molecular selectivity. Immunity 2: 689–697.
   PubMed Web of Science ®Google Scholar
• Segil, N., S. B. Roberts, and N. Heintz. 1991. Cell-cycle-regulated phosphorylation of the transcription factor Oct-1. Cold Spring Harbor Symp. Quant. Biol. 56: 285–292.
   PubMedGoogle Scholar
• Segil, N., S. B. Roberts, and N. Heintz. 1991. Mitotic phosphorylation of the Oct-1 homeodomain and regulation of Oct-1 DNA binding activity. Science 254: 1814–1816.
   PubMedGoogle Scholar
• Sherr, C. J. 1993. Mammalian G1 cyclins. Cell 73: 1059–1065.
   PubMed Web of Science ®Google Scholar
• Sive, H. L., and R. G. Roeder. 1986. Interaction of a common factor with conserved promoter and enhancer sequences in histone H2B, immunoglobulin, and U2 small nuclear RNA (snRNA) genes. Proc. Natl. Acad. Sci. USA 83: 6382–6386.
   PubMed Web of Science ®Google Scholar
• Snow, J. W., N. Abraham, M. C. Ma, N. W. Abbey, B. Herndier, and M. A. Goldsmith. 2002. STAT5 promotes multilineage hematolymphoid development in vivo through effects on early hematopoietic progenitor cells. Blood 99: 95–101.
   PubMedGoogle Scholar
• Socolovsky, M., A. E. Fallon, S. Wang, C. Brugnara, and H. F. Lodish. 1999. Fetal anemia and apoptosis of red cell progenitors in Stat5a−/−5b−/− mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 98: 181–191.
   PubMed Web of Science ®Google Scholar
• Soldaini, E., S. John, S. Moro, J. Bollenbacher, U. Schindler, and W. J. Leonard. 2000. DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol. Cell. Biol. 20: 389–401.
   PubMedGoogle Scholar
• Staudt, L. M., and M. J. Lenardo. 1991. Immunoglobulin gene transcription. Annu. Rev. Immunol. 9: 373–398.
   PubMed Web of Science ®Google Scholar
• Sturm, R. A., G. Das, and W. Herr. 1988. The ubiquitous octamer-binding protein Oct-1 contains a POU domain with a homeo box subdomain. Genes Dev. 2: 1582–1599.
   PubMed Web of Science ®Google Scholar
• Teglund, S., C. McKay, E. Schuetz, J. M. van Deursen, D. Stravopodis, D. Wang, M. Brown, S. Bodner, G. Grosveld, and J. N. Ihle. 1998. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93: 841–850.
   PubMed Web of Science ®Google Scholar
• Wang, D., R. Moriggl, D. Stravopodis, N. Carpino, J. C. Marine, S. Teglund, J. Feng, and J. N. Ihle. 2000. A small amphipathic alpha-helical region is required for transcriptional activities and proteasome-dependent turnover of the tyrosine-phosphorylated Stat5. EMBO J. 19: 392–399.
   PubMedGoogle Scholar
• Wang, Z., Y. Zhang, D. Kamen, E. Lees, and K. Ravid. 1995. Cyclin D3 is essential for megakaryocytopoiesis. Blood 86: 3783–3788.
   PubMed Web of Science ®Google Scholar
• Watanabe, G., C. Albanese, R. J. Lee, A. Reutens, G. Vairo, B. Henglein, and R. G. Pestell. 1998. Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1. Mol. Cell. Biol. 18: 3212–3222.
   PubMed Web of Science ®Google Scholar
• Wegner, M., D. W. Drolet, and M. G. Rosenfeld. 1993. POU-domain proteins: structure and function of developmental regulators. Curr. Opin. Cell Biol. 5: 488–498.
   PubMedGoogle Scholar
• Yan, G. Z., and E. B. Ziff. 1997. Nerve growth factor induces transcription of the p21 WAF1/CIP1 and cyclin D1 genes in PC12 cells by activating the Sp1 transcription factor. J. Neurosci. 17: 6122–6132.
   PubMed Web of Science ®Google Scholar
• Zhang, S., S. Fukuda, Y. Lee, G. Hangoc, S. Cooper, R. Spolski, W. J. Leonard, and H. E. Broxmeyer. 2000. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J. Exp. Med. 192: 719–728.
   PubMed Web of Science ®Google Scholar